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Abstract Protein kinase D (PKD) targets several proteins
in the heart, including cardiac troponin I (cTnI) and class II
histone deacetylases, and regulates cardiac contraction and
hypertrophy. In adult rat ventricular myocytes (ARVM),
PKD activation by endothelin-1 (ET1) occurs via protein
kinase Ce and is attenuated by cAMP-dependent protein
kinase (PKA). Intracellular compartmentalisation of
cAMP, arising from localised activity of distinct cyclic
nucleotide phosphodiesterase (PDE) isoforms, may result
in spatially constrained regulation of the PKA activity that
inhibits PKD activation. We have investigated the roles of
the predominant cardiac PDE isoforms, PDE2, PDE3 and
PDE4, in PKA-mediated inhibition of PKD activation.
Pretreatment of ARVM with the non-selective PDE
inhibitor isobutylmethylxanthine (IBMX) attenuated sub-
sequent PKD activation by ET1. However, selective inhi-
bition of PDE2 [by erythro-9-(2-hydroxy-3-nonyl)
adenine, EHNA], PDE3 (by cilostamide) or PDE4 (by
rolipram) individually had no effect on ET1-induced PKD
activation. Selective inhibition of individual PDE isoforms
also had no effect on the phosphorylation status of the
established cardiac PKA substrates phospholamban (PLB;
at Ser16) and cTnI (at Ser22/23), which increased mark-
edly with IBMX. Combined administration of cilostamide
and rolipram, like IBMX alone, attenuated ET1-induced
PKD activation and increased PLB and cTnI phosphory-
lation, while combined administration of EHNA and
cilostamide or EHNA and rolipram was ineffective. Thus,
cAMP pools controlled by PDE3 and PDE4, but not PDE2,
regulate the PKA activity that inhibits ET1-induced PKD
activation. Furthermore, PDE3 and PDE4 play redundant
roles in this process, such that inhibition of both isoforms
is required to achieve PKA-mediated attenuation of PKD
activation.
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Abbreviations
AKAP A-kinase anchoring protein
AR Adrenergic receptor
ARVM Adult rat ventricular myocytes
cTnI Cardiac troponin I
DAG Diacylglycerol
EHNA Erythro-9-(2-hydroxy-3-nonyl) adenine
ET1 Endothelin-1
GqPCR Gq protein-coupled receptor
HDAC Histone deacetylase
IBMX 3-isobutyl-1-methylxanthine
ISO Isoprenaline
mM199 Modiﬁed M199
PDE Phosphodiesterase
PE Phenylephrine
PKA cAMP-dependent protein kinase
PKC Protein kinase C
PKD Protein kinase D
PLB Phospholamban
PLC Phospholipase C
R. S. Haworth (&)   F. Cuello   M. Avkiran
King’s College London British Heart Foundation Centre,
Cardiovascular Division, King’s College London,
The Rayne Institute, St Thomas’ Hospital,
Lambeth Palace Road, London SE1 7EH, UK
e-mail: robert.haworth@kcl.ac.uk
123
Basic Res Cardiol (2011) 106:51–63
DOI 10.1007/s00395-010-0116-1Introduction
Protein kinase D (PKD) is a serine/threonine kinase that
consists of an N-terminal regulatory domain (containing
two cysteine-rich zinc ﬁnger-like motifs and a pleckstrin
homology domain) and a C-terminal catalytic domain [20,
34]. PKD has been shown to be activated in vitro by
diacylglycerol (DAG) and 12-phorbol 13-myristate ester
(PMA) [35]. In addition, phosphorylation of Ser744 and
Ser748 in the kinase activation loop of PKD by protein
kinase C (PKC) results in DAG-independent catalytic
activity [42]. Although PKD can act either in parallel with
or downstream of PKC, previous studies suggest that the
latter is the principal mechanism of PKD activation in
various cell types [7, 39, 42].
Previously, we have shown that PKD regulates myoﬁl-
ament Ca
2? sensitivity, most likely through its phosphor-
ylation of cardiac troponin I (cTnI) [8, 15], which we have
conﬁrmed recently using mouse myocardium expressing
non-phosphorylatable cTnI [5]. In addition, work from the
Olson laboratory [14, 37] has shown that PMA and the
a1-adrenergic receptor (AR) agonist phenylephrine (PE)
induce cardiac hypertrophy in neonatal rat ventricular
myocytes by a PKD-dependent mechanism, which involves
the direct phosphorylation and subsequent nuclear export
of histone deacetylase 5 (HDAC5). A role for PKD in
HDAC5 redistribution has been supported by studies in
failing rabbit and human myocardium [6], and recent evi-
dence from mice with cardiac-speciﬁc PKD deletion indi-
cate that PKD is necessary for the full manifestation of
pathological cardiac remodelling in response to stress [13].
Taken together, these ﬁndings indicate that PKD plays
multiple important roles in cardiac myocytes, making it
imperative to better understand the mechanisms that reg-
ulate its activity in this cell type.
We have previously investigated the roles of PKC iso-
forms and cAMP-dependent protein kinase (PKA) in the
regulation of PKD activity in adult rat ventricular myocytes
(ARVM) [17]. We found that PKCe plays a predominant
role in endothelin-1 (ET1)-induced PKD activation and
such activation is inhibited by a PKA-mediated pathway.
This counter regulation of PKD by PKA could have
important implications, both under normal circumstances
where PKA activity is likely to suppress PKD activation
and circumstances where PKA activation is impaired, such
as in heart failure [22]. Myocardial PKA activity is thought
to be controlled in a localised manner through several
mechanisms, including the binding of PKA regulatory
subunits to A-kinase anchoring proteins (AKAPs) [12] and
the maintenance of discrete cAMP pools by the breakdown
of cAMP by compartmentalised phosphodiesterase (PDE)
isoforms [4, 27, 36, 40]. The principal PDE isoforms that
target cAMP in cardiac myocytes are believed to be PDE2,
PDE3 and PDE4 [38], and it has been suggested that these
isoforms have distinct roles in regulating PKA activity in
different subcellular compartments, and thereby control
different downstream events [21, 26–28, 31, 38, 41].
The principal aim of the present study was to determine
if the PKA activity that inhibits PKD activation in ARVM
is under the control of distinct PDE isoform(s) in a com-
partmentalised manner. Our ﬁndings indicate that in the
presence of basal adenylate cyclase activity, PDE3 and
PDE4 regulate the PKA activity that inhibits PKD activa-
tion in a redundant manner. However, we ﬁnd no evidence
for a speciﬁc role for PDE3 and PDE4 in this process, since
PKA-mediated inhibition of PKD activation (which is
likely to occur at the sarcolemma) and PKA-mediated
phosphorylation of cTnI (at the sarcomere) and phospho-
lamban (PLB; at the sarcoplasmic reticulum) were simi-
larly regulated by these PDE isoforms.
Materials and methods
Materials and animals
Antibodies for PKD, pSer916 PKD, pSer744/748 PKD
and pSer22/3 cTnI were from Cell Signaling Technology,
PLB and pSer16 PLB were from Badrilla, and pSer498
HDAC5 was from Abcam. Horseradish peroxidase-con-
jugated secondary antibodies and enhanced chemilumi-
nescence reagents were from GE Healthcare. Isoprenaline
(ISO) and PE were from Sigma Chemical Co. ET1,
isobutylmethylxanthine (IBMX), erythro-9-(2-hydroxy-3-
nonyl) adenine (EHNA), cilostamide, rolipram and H89
were from Merck. M199, penicillin and streptomycin
were from Invitrogen. The adenoviral vector used to
express full length mouse PKD1 in ARVM was prepared
and used as described earlier [8]. Adult male Wistar rats
(250 g) were from B & K Universal. The investigation
was performed in accordance with the Home Ofﬁce
Guidance on the Operation of the Animals (Scientiﬁc
Procedures) Act 1986, published by Her Majesty’s Sta-
tionery Ofﬁce.
Short term culture and adenoviral infection of ARVM
ARVM were isolated as described earlier [30, 33], and
washed with modiﬁed M199 medium [mM199; M199
medium with added penicillin (100 IU/ml), streptomycin
(100 IU/ml), L-carnitine (2 mM), creatine (5 mM) and
taurine (5 mM)]. The cell suspension was centrifuged at
100g for 2 min to pellet the myocytes, which were then
resuspended in mM199 medium. To each well of a
laminated 6-well culture plate, 2 ml of cell suspension
was added and the plates were maintained in a
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123humidiﬁed 5% CO2 incubator at 37C. After 2 h of pre-
plating, the medium was aspirated, leaving only adherent
cells, and 2 ml of fresh, pre-warmed mM199 medium
was added.
Adenoviral infection of cultured myocytes was per-
formed after the initial pre-plating step, in order to elevate
PKD expression to a readily detectable level. Myocytes
were exposed to adenovirus at a multiplicity of infection of
10 plaque forming units/cell for 2 h at 37C, before the
medium containing residual virus was aspirated and
replaced with fresh, pre-warmed (37C) mM199 medium.
ARVM were maintained in culture for 18 h before use in
experiments.
Pharmacological protocols
Cells were exposed to ET1 (100 nM), PE (10 lM) or
vehicle (PBS, 0.1% volume) for 10 min prior to harvesting.
ISO (100 nM), the non-selective PDE inhibitor IBMX
(100 lM in DMSO) or the isoform-selective PDE inhibi-
tors EHNA (PDE2; 10 lM in water), cilostamide (PDE3;
10 lM in DMSO) or rolipram (PDE4; 10 lM in DMSO)
were added to cells 10 min prior to ET1 or PE and were
present throughout the rest of the protocol. Control cells
were exposed to the ﬁnal concentrations of the appropriate
inhibitor vehicle for the equivalent period. In some
experiments, cells were ﬁrst exposed to the PKA inhibitor
H89 (10 lM) or vehicle (DMSO) for 30 min prior to
subsequent additions. PDE inhibitor concentrations were
selected on the basis of previous studies investigating PDE
isoform functions in cardiac myocytes [10, 11, 26], while
the ISO, PE, ET1 and H89 concentrations were based on
our previous work [9, 17].
Western blotting
Cells were washed once with PBS, lysed in Laemmli buffer
and protein samples separated by SDS-PAGE. After
transfer to nitrocellulose membrane (pSer498 HDAC5
blots) or PVDF membrane (all other blots), western anal-
ysis was performed. Where both phosphorylated and total
protein were determined, duplicate blots were used. Bound
antibody was detected by labelling with horseradish per-
oxidase-conjugated secondary antibody followed by
enhanced chemiluminescence. Phosphorylation status was
quantiﬁed using a densitometer (BioRad GS-800). To
permit comparison between experiments analysed on dif-
ferent gels, all quantitative data were normalised to the
vehicle-treated samples exposed to ET1 or PE in each
experiment. The corresponding vehicle control value was
subtracted from each ET1 or PE value to give the agonist-
induced change in signal intensity under each condition.
Quantitative data are presented as mean ± SD from 3–4
independent experiments (as indicated in the legends to
each ﬁgure).
Measurement of the [Ca
2?]i transient and sarcomere
shortening
[Ca
2?]i transient and sarcomere shortening were monitored
simultaneously, essentially as we have described previ-
ously [8]. ARVM were cultured overnight on glass cov-
erslips, transferred to a superfusion chamber on the stage of
a Nikon Eclipse TE300 inverted microscope and continu-
ously superfused with Tyrode’s solution [NaCl (137 mM),
KCl (5.4 mM), CaCl2 (1.0 mM), MgCl2 (0.5 mM), N-2-
hydroxyethylpiperazine-N0-2-ethanesulfonic acid (10 mM;
pH 7.4) and glucose (10 mM)]. Cells were loaded with the
ﬂuorescent Ca
2? indicator fura-2 AM (2 lM for
10–12 min). Sarcomere lengths and Ca
2? transients were
measured from single myocytes using IonOptix equipment
and software. After a 2 min stabilisation period in Tyrode’s
solution, PDE inhibitors or vehicle were superfused for
4 min, followed by ISO (10 nM) for 5 min. Quantitative
data are presented as the mean ± SEM for 8–9
experiments.
In vitro kinase assays
Following various treatments, cells were lysed and PKD
was immunoprecipitated as described earlier [16, 17]. In
vitro kinase assays were performed using the immunopre-
cipitated kinase and recombinant cTnI (100 pmol/reaction)
at 30C for 15 min, in the presence of [
32P]-labelled ATP
(100 lM). The reaction was stopped by the addition of
Laemmli sample buffer. cTnI was resolved on a 12%
polyacrylamide gel, which was subsequently dried and
subjected to autoradiography.
Statistical analysis
Inter-group comparisons were by analysis of variance
(ANOVA), followed by Bonferroni t test. P\0.05 was
considered signiﬁcant.
Results
Non-selective PDE inhibition inhibits ET1-induced
PKD activation
We ﬁrst determined whether non-selective PDE inhibition
inhibits ET1-induced PKD activation in ARVM. The
phosphorylation status of heterologously expressed PKD at
Ser916 (autophosphorylation) and Ser744/748 (activation
loop phosphorylation by PKC) was determined by western
Basic Res Cardiol (2011) 106:51–63 53
123blotting. As illustrated in Fig. 1a and shown quantitatively
in Fig. 1b, exposure of ARVM to ET1 (100 nM for
10 min) promoted robust phosphorylation of PKD at both
the activation loop sites and the autophosphorylation site,
reﬂecting PKC-dependent activation of PKD. Consistent
with our previous work [17], pretreatment with the b-AR
agonist ISO (100 nM for 10 min) substantially reduced
ET1-induced PKD phosphorylation. Pretreatment with the
non-selective PDE inhibitor IBMX (100 lM for 10 min)
also reduced ET1-induced PKD phosphorylation at both
the Ser744/748 and the Ser916 sites to a similar level to
that achieved with ISO pretreatment. This suggests that
global PDE inhibition in the presence of basal adenylate
cyclase activity produces a sufﬁcient increase in PKA
activity in the relevant compartment to inhibit PKD
activation.
As a further indicator of PKD catalytic activity (in
addition to autophosphorylation at Ser916), we used a
phosphospeciﬁc antibody that recognises phosphorylation
of the PKD target site in HDAC5, Ser498. As shown in
Fig. 1, this antibody detected ET1-induced increases in the
phosphorylation of two proteins, migrating at around
140 kDa (upper band) and 105 kDa (lower band). The
ET1-induced increase in phosphorylation of the lower band
protein was attenuated by pretreatment with either ISO or
IBMX, mirroring the effects of these interventions on PKD
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Fig. 1 ET1-induced PKD
activation is inhibited by
pretreatment with IBMX or
isoprenaline. Cultured ARVM
were exposed to vehicle, IBMX
(100 lM) or ISO (100 nM) for
10 min, followed by vehicle
(con) or ET1 (100 nM) for
10 min. a Representative
western blots of phosphoSer916
PKD, phosphoSer744/748 PKD,
phosphoSer498 HDAC5 and
total PKD, as indicated.
b Quantitative data for the ET1-
induced change in
phosphoSer916 PKD,
phosphoSer744/748 PKD, and
the upper and lower bands from
the pSer498 HDAC5 blots
(n = 4). *P\0.05 versus
vehicle control
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123phosphorylation. Interestingly, the ET1-induced increase in
phosphorylation of the upper band protein was not signif-
icantly affected by pretreatment with IBMX, despite its
marked effect on PKD phosphorylation, but was slightly
but signiﬁcantly attenuated by pretreatment with ISO.
Although the molecular identities of the proteins repre-
senting the upper and lower bands detected by the pSer498
HDAC5 antibody remain to be established, they are likely
to represent different HDAC isoforms (see ‘‘Discussion’’).
Since the phosphorylation status of the lower HDAC band
more faithfully reﬂected the changes in the phosphoryla-
tion status of PKD, this was subsequently used as an
indicator of PKD catalytic activity.
Selective inhibition of individual PDE isoforms
does not inhibit ET1-induced PKD activation
To determine whether any individual PDE isoform is pre-
dominantly responsible for regulating the PKA activity that
impacts PKD activation, we determined the effects of
pretreatment with the PDE2-selective inhibitor EHNA, the
PDE3-selective inhibitor cilostamide or the PDE4-selective
inhibitor rolipram. As shown in Fig. 2, none of the iso-
form-selective PDE inhibitors had a marked effect on
subsequent ET1-induced PKD phosphorylation and acti-
vation, while pretreatment with ISO again produced a
consistent inhibitory effect.
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Fig. 2 ET1-induced PKD
activation is not inhibited by
pretreatment with individual
isoform-selective PDE
inhibitors. Cultured ARVM
were exposed to vehicle, EHNA
(10 lM), cilostamide (10 lM),
rolipram (10 lM) or ISO
(100 nM) for 10 min, followed
by vehicle (con) or ET1
(100 nM) for 10 min.
a Representative western blots
of phosphoSer916 PKD,
phosphoSer744/748 PKD,
phosphoSer498 HDAC5 and
total PKD, as indicated.
b Quantitative data for the ET1-
induced change in
phosphoSer916 PKD,
phosphoSer744/748 PKD, and
the lower bands from the
pSer498 HDAC5 blots (n = 3).
*P\0.05 versus vehicle
control
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123The lack of effect of the isoform-selective PDE inhibi-
tors on ET1-induced PKD activation could be due to their
failure to elevate cAMP and activate PKA in the relevant
myocyte compartment. To explore whether the isoform-
selective PDE inhibitors have a different impact on PKA
activity in other myocyte compartments, we also examined
their effects on the phosphorylation status of cTnI and
PLB. As shown in Fig. 3, whilst non-selective PDE inhi-
bition with IBMX or exposure to ISO markedly increased
the phosphorylation of cTnI and PLB at their PKA sites,
the isoform-selective PDE inhibitors produced little effect.
These ﬁndings suggest that in the presence of basal aden-
ylate cyclase activity, inhibition of any individual PDE
isoform fails to produce a sufﬁcient increase in PKA
activity in the myocyte compartments that facilitate the
inhibition of PKD activation or the induction of cTnI or
PLB phosphorylation.
Combined inhibition of PDE3 and PDE4 is required
to induce cTnI and PLB phosphorylation
We next determined the effects of the simultaneous inhi-
bition of two or more PDE isoforms on PKA activity in the
myocyte compartments that facilitate the phosphorylation
of cTnI in the sarcomere or PLB at the sarcoplasmic
reticulum. As shown in Fig. 4, the PDE2-selective inhibitor
EHNA together with either the PDE3-selective inhibitor
cilostamide or the PDE4-selective inhibitor rolipram was
unable to promote PKA activity in these compartments, as
reﬂected by a lack of effect on the phosphorylation status
of cTnI or PLB. However, the combination of the PDE3-
and PDE4-selective inhibitors was sufﬁcient to promote
phosphorylation of both cTnI and PLB, to an extent similar
to that achieved by the combination of all three isoform-
selective inhibitors or the use of the non-selective PDE
inhibitor IBMX. These ﬁndings suggest that in the presence
of basal adenylate cyclase activity, PDE3 and PDE4 are the
principal PDE isoforms that determine PKA activity in the
myocyte compartments that facilitate the phosphorylation
of cTnI and PLB.
Combined inhibition of PDE3 and PDE4 produces
inotropic and lusitropic effects
As the combination of PDE3- and PDE4-selective inhib-
itors was sufﬁcient to promote phosphorylation of both
cTnI and PLB, we investigated the functional effects of
this treatment in single cells. The combination of cilo-
stamide and rolipram produced a signiﬁcant increase in
twitch amplitude (Fig. 5a), and this increase was similar
in magnitude to that seen with 10 nM ISO (Fig. 5b). The
twitch relaxation rate was also increased signiﬁcantly by
exposure to either cilostamide and rolipram or ISO
(Fig. 5b). Additionally, the combination of cilostamide
and rolipram produced a signiﬁcant increase in the
[Ca
2?]i transient amplitude and a signiﬁcant decrease in
the [Ca
2?]i transient decay time constant (Fig. 5c), with
the magnitude of these changes again similar to those
seen in response to ISO (Fig. 5d). These ﬁndings suggest
that, in the presence of basal adenylate cyclase activity,
combined inhibition of PDE3 and PDE4 elevates PKA
activity in the relevant compartments to a sufﬁcient extent
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Fig. 3 PKA-mediated
phosphorylation of cTnI and
PLB is not induced by
pretreatment with individual
isoform-selective PDE
inhibitors. Cultured ARVM
were exposed to vehicle, IBMX
(100 lM), EHNA (10 lM),
cilostamide (10 lM), rolipram
(10 lM) or ISO (100 nM) for
10 min, followed by vehicle
(con) or ET1 (100 nM) for
10 min. Representative western
blots of phosphoSer22/23 cTnI,
phosphoSer16 PLB and total
PLB, as indicated
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123to signiﬁcantly modify Ca
2? transients and myocyte
contraction and relaxation.
Combined inhibition of PDE3 and PDE4 is required
to inhibit ET1-induced PKD activation
To determine whether PDE3 and PDE4 also regulate the
PKA activity that inhibits PKD activation, we investigated
the effects of the isoform-selective PDE inhibitor combi-
nations on ET1-induced PKD activation. As shown in
Fig. 6, only pretreatment with the combination of PDE3-
selective inhibitor cilostamide and PDE4-selective inhibi-
tor rolipram was able to markedly inhibit ET1-induced
PKD activation. These ﬁndings indicate that PDE3 and
PDE4 are also the principal PDE isoforms that regulate the
PKA activity involved in inhibiting ET1-induced PKD
activation.
To conﬁrm that the phosphorylation status of Ser916
faithfully reﬂects the activation status of PKD, we also
determined PKD activity by in vitro kinase assays using
recombinant cTnI as a substrate. As shown in Fig. 7,
exposure of cells to ET1 promoted robust phosphorylation
of cTnI by immunoprecipitated PKD in these assays, and
this effect was completely blocked by pretreatment of cells
with ISO, as we have reported before [17]. Pretreatment
with IBMX or the combination of cilostamide and rolipram
also substantially reduced cTnI phosphorylation in these
assays (Fig. 7), essentially reﬂecting the changes observed
in PKD phosphorylation at Ser916 and Ser744/748 in
earlier experiments (Figs. 1, 6). These ﬁndings conﬁrm that
in this preparation, PKD phosphorylation status at Ser916
is a robust index of PKD activity.
PKA mediates the inhibition of ET1-induced PKD
activation by combined inhibition of PDE3 and PDE4
To determine whether the combined inhibition of PDE3
and PDE4 inhibits ET1-induced PKD activation through
increasing the PKA activity in the relevant compartment
rather than through some non-speciﬁc effects of cilosta-
mide and rolipram, we investigated the effect of the PKA
inhibitor H89 on this response. As shown in Fig. 8, pre-
treatment with H89 efﬁciently blocked the inhibitory
effects of combined cilostamide and rolipram, or indeed
ISO (as we have shown before [17]), on ET1-induced PKD
activation. These ﬁndings indicate that combined inhibition
of PDE3 and PDE4 inhibits ET1-induced PKD activation
through increased PKA activity.
PKA activation inhibits PE-induced PKD activation
Finally, we determined whether PKA activation by pre-
treatment with the non-selective PDE inhibitor IBMX or
the b-AR agonist ISO also inhibits PKD activation by
members of the Gq protein-coupled receptor (GqPCR)
family other than ET1 receptors. As shown in Fig. 9,
exposure of ARVM to the a1-AR agonist PE induced
robust PKD activation. PE-induced PKD activation was
inhibited by pretreatment with IBMX or ISO (Fig. 9),
mirroring our earlier ﬁndings with ET1-induced PKD
activation (Fig. 1). These ﬁndings suggest that in cardiac
myocytes PKA activity may inhibit subsequent PKD acti-
vation by multiple GqPCR pathways, including those
stimulated by a1-ARs and ET1 receptors.
A
p22/23 cTnI
p16 PLB
ttl P L B
veh
total PLB
EHNA
cil 
EHNA
rol
IBMX
cil
rol
EHNA
cil
rol
B
1.5
pS22/23 cTnI
*
0.5
1.0 *
s
i
g
n
a
l
 
i
n
t
e
n
s
i
t
y
 
n
o
r
m
a
l
i
s
e
d
t
o
 
I
B
M
X
 
(
a
r
b
.
 
u
n
i
t
s
)
0.0
1.0
1.5
*
pS16 PLB
*
0.0
0.5
s
i
g
n
a
l
 
i
n
t
e
n
s
i
t
y
 
n
o
r
m
a
l
i
s
e
d
t
o
 
I
B
M
X
 
(
a
r
b
.
 
u
n
i
t
s
)
veh EHNA
cil 
EHNA
rol
cil
rol
EHNA
cil
rol
Fig. 4 PKA-mediated phosphorylation of cTnI and PLB requires
inhibition of both PDE3 and PDE4. Cultured ARVM were exposed to
vehicle, various combinations of EHNA (10 lM), cilostamide
(10 lM) and rolipram (10 lM), or IBMX (100 lM) for 10 min.
a Representative western blots of phosphoSer22/23 cTnI, phospho-
Ser16 PLB and total PLB, as indicated (n = 3). b Quantitative data
for the change in phosphoSer22/23 cTnI and phosphoSer16 PLB
normalised to that seen with IBMX (n = 3). *P\0.05 versus vehicle
control
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Fig. 5 Combined inhibition of
PDE3 and PDE4 induces
inotropic and lusitropic changes.
Cultured ARVM were exposed
to Tyrode’s solution for 2 min,
vehicle or combined cilostamide
(10 lM) and rolipram (10 lM)
for 4 min, and then ISO
(10 nM) for 5 min.
a Representative signal-
averaged (14 twitches)
contractility recordings for each
treatment. b Quantitative data
for sarcomere shortening and
relaxation rate, as indicated
(n = 8–9 cells/group).
c Representative signal-
averaged (14 twitches) [Ca
2?]i
transient recordings for each
treatment. d Quantitative data
for changes in [Ca
2?]i transient
amplitude and decay time
constant, as indicated (n = 8–9
cells/group). *P\0.05 versus
vehicle control
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123Discussion
The major ﬁndings of this study are that in adult cardiac
ventricular myocytes: (1) PDE3 and PDE4 regulate the
PKA activity that inhibits ET1-induced PKD activation; (2)
the PKA activities that are responsible for PLB phos-
phorylation at the sarcoplasmic reticulum and cTnI phos-
phorylation within the sarcomere are also regulated by the
same PDE isoforms, PDE3 and PDE4; (3) PDE3 and PDE4
appear to operate in a redundant manner in the above
process, such that their individual inhibition has little
impact but their combined inhibition markedly increases
PKA activity; (4) PKA activation, either by non-selective
PDE inhibition or by b-AR stimulation, inhibits PKD
activation not only by ET1 but also by a1-AR stimulation,
suggesting that the pertinent inhibitory crosstalk mecha-
nism regulates PKD activation by multiple GqPCR sig-
nalling pathways.
The marked inhibitory effect of the non-selective PDE
inhibitor IBMX on ET1-induced PKD activation is
consistent with our earlier study that ﬁrst reported a PKA-
mediated inhibitory crosstalk mechanism in PKD regula-
tion [17], and additionally suggests that PDE inhibition
produces a sufﬁcient increase in the PKA activity that
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Fig. 6 Inhibition of ET1-
induced PKD activation
requires inhibition of both
PDE3 and PDE4. Cultured
ARVM were exposed to
vehicle, various combinations of
EHNA (10 lM), cilostamide
(10 lM) and rolipram (10 lM),
or ISO (100 nM) for 10 min,
followed by vehicle (con) or
ET1 (100 nM) for 10 min.
a Representative western blots
of phosphoSer916 PKD,
phosphoSer744/748 PKD,
phosphoSer498 HDAC5 and
total PKD, as indicated.
b Quantitative data for the ET1-
induced change in
phosphoSer916 PKD,
phosphoSer744/748 PKD, and
the lower bands from the
pSer498 HDAC5 blots (n = 3).
*P\0.05 versus vehicle
control
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123inhibits PKD activation, even in the absence of receptor-
mediated adenylate cyclase stimulation. The data we have
obtained with isoform-selective PDE inhibitors indicate
that PDE3 and PDE4 are the principal isoforms that reg-
ulate the pertinent PKA activity, and that these PDE iso-
forms operate in a redundant manner, such that inhibition
of both is required to achieve marked inhibition of PKD
activation. Upon exposure of myocytes to ET1, PKC-
mediated PKD activation is likely to occur at the sarco-
lemma, following the recruitment of novel PKC isoforms
and PKD itself to this compartment through the interaction
of their cysteine-rich zinc ﬁnger domains with DAG within
the lipid bilayer and DAG-mediated PKC activation [2].
On the basis of our current ﬁndings, it is reasonable to
speculate that PDE3 and PDE4 are responsible for regu-
lating cAMP levels and therefore PKA activity at a sar-
colemmal compartment where PKD activation occurs.
Consistent with such a possibility, in unstimulated ARVM,
the combined inhibition of PDE3 and PDE4 has been
shown to increase the activity of a sarcolemmal PKA tar-
get, the L-type Ca
2? channel [38], while the individual
inhibition of PDE2, PDE3 or PDE4 was without effect [31,
38].
On the other hand, our ﬁndings regarding the phos-
phorylation of known PKA targets in other myocyte
compartments argue against speciﬁc roles for PDE3
and PDE4 in regulating PKA activity exclusively at a
sarcolemmal compartment. We have found that the com-
bined inhibition of PDE3 and PDE4 was sufﬁcient and
necessary also for inducing marked phosphorylation of
cTnI and PLB at their PKA-targeted residues and produc-
ing signiﬁcant functional effects on myocyte contraction,
relaxation and Ca
2? transients, indicating that PDE3 and
PDE4 regulate PKA activities additionally at sarcomeric
and sarcoplasmic reticular compartments. In this context, it
is worth noting that PDE3 and PDE4 are responsible for the
vast majority of the total PDE activity in rat cardiac
myocytes [26, 31]. It is possible, therefore, that the similar
effects of the various PDE inhibitors on PKD activation
and cTnI and PLB phosphorylation in our studies reﬂect
their quantitative effects on total cellular PDE activity,
rather than indicating speciﬁc roles for PDE3 and PDE4 in
regulating PKA activity in deﬁned subcellular compart-
ments. Nevertheless, compartment-speciﬁc roles of PDE
isoforms may become more evident in the presence of
receptor-mediated stimulation of cAMP generation by
adenylate cyclase; indeed, while combined inhibition of
PDE3 and PDE4 was required to increase L-type Ca
2?
channel activity in unstimulated ARVM [38], PDE4 inhi-
bition alone was sufﬁcient to potentiate the induction of
such channel activity by sub-maximal b-AR stimulation
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Fig. 7 PDE inhibition regulates ET1-induced PKD activity. Cultured
ARVM were exposed to vehicle, IBMX (100 lM), cilostamide
(10 lM) and rolipram (10 lM), or ISO (100 nM) for 10 min,
followed by vehicle (con) or ET1 (100 nM) for 10 min. PKD was
immunoprecipitated from cell lysates and PKD activity was assessed
by in vitro kinase assays using cTnI as substrate. a Representative
autoradiogram of phosphorylated cTnI. b Quantitative data for the
ET1-induced change in cTnI phosphorylation (n = 3). *P\0.05
versus vehicle control
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indicated. b Quantitative data for the ET1-induced change in
phosphoSer916 PKD (n = 3). *P\0.05 versus vehicle control
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123[23, 31, 38]. An interesting corollary ﬁnding in our study
was that combined PDE3 and PDE4 inhibition and b-AR
stimulation each produced comparable effects on myocyte
protein phosphorylation (Fig. 4) and function (Fig. 5),
suggesting the presence of considerable basal adenylate
cyclase activity in this preparation.
In the course of the present study, we have observed a
differential impact of PKA activation, either by PDE
inhibition or by b-AR stimulation, on the appearance of
two phosphoprotein moieties that are detected by the
phospho-Ser498 HDAC5 antibody. ET1 or PE stimulation
markedly increased the phosphorylation of both 140-kDa
moiety and 105-kDa moiety, but the phosphorylation status
of the 105-kDa protein tracked more faithfully the changes
in PKD phosphorylation that arose from PKA activation,
consistent with this protein being a downstream target of
activated PKD. Although the identities of the two phos-
phoproteins cannot be ascertained from the present study, it
is notable that the motif around the PKD target site in
HDAC5, Ser498 (PLSRTQSSPL; underlining indicates the
phosphorylated residue) [19], is quite well conserved
among other members of the class II HDAC family (e.g.
Ser630 in HDAC4, PLSRAQSSPA; Ser457 in HDAC7,
PLSRTQSSPA; Ser449 in HDAC9, PLNRTQSAPL).
Since the phospho-Ser498 HDAC5 antibody was raised
against a synthetic phosphopeptide derived from the
HDAC5 sequence around Ser498, such homology suggests
that the 140- and 105-kDa phosphoproteins detected by this
antibody are likely to be different HDAC isoforms. It
would be important to determine how the phosphorylation
and nuclear export of speciﬁc HDAC isoforms are modu-
lated by the PKA-mediated inhibition of PKD activation
that we have delineated in our previous [17] and current
work, and to investigate the impact of such inhibitory
crosstalk on HDAC-regulated transcriptional reprogram-
ming processes that facilitate cardiac hypertrophy and
remodelling upon neurohormonal stimulation [3]. In this
context, there is evidence in both adult [32] and neonatal
[29] cardiac myocytes that the pro-hypertrophic conse-
quences of a1-AR stimulation are attenuated by b-AR
stimulation through a PKA-mediated pathway, although
the molecular mechanism(s) underlying this phenomenon
have not been deciphered. Furthermore, recent evidence
suggests that in failing myocardium, in which the down-
regulation of b-AR-mediated signalling pathways is a
common phenomenon [25], ET1-induced nuclear export of
HDAC5 is potentiated, at least in part through a PKD-
mediated pathway [6]. These ﬁndings support the possi-
bility that PKA-mediated inhibition of PKD activation is of
physiological signiﬁcance, particularly in the context of
cardiac hypertrophy and failure.
The upstream molecular mechanism(s) that are respon-
sible for PKA-mediated inhibition of PKD activation in
cardiac myocytes remain unknown. Our observation that
PKA activation, either by PDE inhibition or by b-AR
stimulation, inhibits PKD activation both by ET1 and by
PE indicates that the inhibitory crosstalk mechanism reg-
ulates PKD activation by multiple GqPCR signalling
pathways, and suggests that this mechanism must target
one or more components that are common to such path-
ways. Putative PKA targets within the pertinent inhibitory
crosstalk mechanism include phospholipase C (PLC) iso-
forms, since in non-cardiac cells PLC-b2 and -b3 have been
shown to be directly phosphorylated by PKA, resulting in
their inactivation [1, 24]. Furthermore, regulator of G
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Fig. 9 PE-induced PKD activation is inhibited by pretreatment with
IBMX or isoprenaline in ARVM. Cultured ARVM were exposed to
vehicle, IBMX (100 lM) or ISO (100 nM) for 10 min, followed by
vehicle (con) or PE (10 lM) for 10 min. a Representative western
blots of phosphoSer916 PKD, phosphoSer498 HDAC5 and total
PKD, as indicated. b Quantitative data for the PE-induced change in
phosphoSer916 PKD, and the lower band from the pSer498 HDAC5
blots (n = 4). *P\0.05 versus vehicle control
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123protein signalling (RGS) 4 and G protein-coupled receptor
kinase 2 (which contains an RGS domain) have also been
shown to be directly phosphorylated by PKA, with such
phosphorylation increasing their afﬁnity for Gaq and
thereby inhibiting GqPCR-mediated stimulation of PLC
activity [18]. If such proximal inhibitory mechanisms were
operative in cardiac myocytes, however, they would be
expected to attenuate not only PKD activation but also
additional GqPCR-mediated signalling events.
The present study has provided novel information
regarding the mechanisms that regulate PKA-mediated
inhibition of PKD activation in cardiac myocytes, partic-
ularly by revealing the roles of PDE3 and PDE4 and by
showing that the inhibitory crosstalk process affects PKD
activation by multiple GqPCR-mediated pathways. Further
work is required to determine both the downstream func-
tional consequences and the upstream molecular mecha-
nisms of such crosstalk.
Acknowledgments This work was supported by a Project Grant
from the British Heart Foundation (PG/08/064/25398). We thank
Shiney Reji for assistance with myocyte isolation and Ajay Doal for
help with preliminary experiments.
Conﬂict of interest None.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided the original author(s) and source are credited.
References
1. Ali H, Fisher I, Haribabu B, Richardson RM, Snyderman R
(1997) Role of phospholipase Cb3 phosphorylation in the
desensitization of cellular responses to platelet-activating factor.
J Biol Chem 272:11706–11709
2. Avkiran M, Rowland AJ, Cuello F, Haworth RS (2008) Protein
kinase D in the cardiovascular system: emerging roles in health
and disease. Circ Res 102:157–163
3. Backs J, Olson EN (2006) Control of cardiac growth by histone
acetylation/deacetylation. Circ Res 98:15–24
4. Baillie GS (2009) Compartmentalized signalling: spatial regula-
tion of cAMP by the action of compartmentalized phosphodies-
terases. FEBS J 276:1790–1799
5. Bardswell SC, Cuello F, Rowland AJ, Gautel M, Walker JW,
Kentish JC, Avkiran M (2010) Distinct sarcomeric substrates are
responsible for protein kinase D-mediated regulation of cardiac
myoﬁlament Ca
2? sensitivity and crossbridge cycling. J Biol
Chem 285:5674–5682
6. Bossuyt J, Helmstadter K, Wu X, Clements-Jewry H, Haworth
RS, Avkiran M, Martin JL, Pogwizd SM, Bers DM (2008)
CaMKIId and PKD overexpression reinforce the HDAC5 redis-
tribution in heart failure. Circ Res 102:695–702
7. Chiu T, Rozengurt E (2001) PKD in intestinal epithelial cells:
rapid activation by phorbol esters, LPA, and angiotensin through
PKC. Am J Physiol Cell Physiol 280:C929–C942
8. Cuello F, Bardswell SC, Haworth RS, Yin X, Lutz S, Wieland
T, Mayr M, Kentish JC, Avkiran M (2007) Protein kinase D
selectively targets cardiac troponin I and regulates myoﬁla-
ment Ca
2? sensitivity in ventricular myocytes. Circ Res
100:864–873
9. Cuello F, Snabaitis AK, Cohen MS, Taunton J, Avkiran M (2007)
Evidence for direct regulation of myocardial Na
?/H
? exchanger
isoform 1 phosphorylation and activity by 90-kDa ribosomal S6
kinase (RSK): effects of the novel and speciﬁc RSK inhibitor fmk
on responses to alpha1-adrenergic stimulation. Mol Pharmacol
71:799–806
10. de Arcangelis V, Soto D, Xiang Y (2008) Phosphodiesterase 4
and phosphatase 2A differentially regulate cAMP/protein kinase
A signaling for cardiac myocyte contraction under stimulation of
b1 adrenergic receptors. Mol Pharmacol 74:1453–1462
11. Di Benedetto G, Zoccarato A, Lissandron V, Terrin A, Li X,
Houslay MD, Baillie GS, Zaccolo M (2008) Protein kinase A
type I and type II deﬁne distinct intracellular signaling com-
partments. Circ Res 103:836–844
12. Dodge-Kafka KL, Langeberg L, Scott JD (2006) Compartmen-
tation of cyclic nucleotide signaling in the heart: the role of
A-kinase anchoring proteins. Circ Res 98:993–1001
13. Fielitz J, Kim MS, Shelton JM, Qi X, Hill JA, Richardson JA,
Bassel-Duby R, Olson EN (2008) Requirement of protein kinase
D1 for pathological cardiac remodeling. Proc Natl Acad Sci USA
105:3059–3063
14. Harrison BC, Kim M, van Rooij E, Plato CF, Papst PJ, Vega RB,
McAnally JA, Richardson JA, Bassel-Duby R, Olson EN,
McKinsey TA (2006) Regulation of cardiac stress signaling by
protein kinase D1. Mol Cell Biol 26:3875–3888
15. Haworth RS, Cuello F, Herron TJ, Frantzen G, Kentish JC,
Gautel M, Avkiran M (2004) Protein kinase D is a novel mediator
of cardiac troponin I phosphorylation and regulates myoﬁlament
function. Circ Res 95:1091–1099
16. Haworth RS, Goss MW, Rozengurt E, Avkiran M (2000)
Expression and activity of protein kinase D/protein kinase Cl in
myocardium: evidence for a1-adrenergic receptor- and protein
kinase C-mediated regulation. J Mol Cell Cardiol 32:1013–1023
17. Haworth RS, Roberts NA, Cuello F, Avkiran M (2007) Regula-
tion of protein kinase D activity in adult myocardium: novel
counter-regulatory roles for protein kinase Ce and protein kinase
A. J Mol Cell Cardiol 43:686–695
18. Huang J, Zhou HZ, Mahavadi S, Sriwai W, Murthy KS (2007)
Inhibition of Gaq-dependent PLC-b1 activity by PKG and PKA is
mediated by phosphorylation of RGS4 and GRK2. Am J Physiol
Cell Physiol 292:C200–C208
19. Huynh QK, McKinsey TA (2006) Protein kinase D directly
phosphorylates histone deacetylase 5 via a random sequential
kinetic mechanism. Arch Biochem Biophys 450:141–148
20. Johannes FJ, Prestle J, Eis S, Oberhagemann P, Pﬁzenmaier K
(1994) PKCl is a novel, atypical member of the protein kinase C
family. J Biol Chem 269:6140–6148
21. Kerfant B-G, Zhao D, Lorenzen-Schmidt I, Wilson LS, Cai S,
Chen SRW, Maurice DH, Backx PH (2007) PI3 Kc is required
for PDE4, not PDE3, activity in subcellular microdomains
containing the sarcoplasmic reticular calcium ATPase in cardio-
myocytes. Circ Res 101:400–408
22. Leineweber K, Bohm M, Heusch G (2006) Cyclic adenosine
monophosphate in acute myocardial infarction with heart failure.
Slayer or savior? Circulation 114:365–367
23. Leroy J, Abi-Gerges A, Nikolaev VO, Richter W, Lechene P,
Mazet J-L, Conti M, Fischmeister R, Vandecasteele G (2008)
Spatiotemporal dynamics of b-adrenergic cAMP signals and
L-type Ca
2? channel regulation in adult rat ventricular myocytes.
Circ Res 102:1091–1100
62 Basic Res Cardiol (2011) 106:51–63
12324. Liu M, Simon MI (1996) Regulation by cAMP-dependent protein
kinase of a G-protein-mediated phospholipase C. Nature
382:83–87
25. Lohse MJ, Engelhardt S, Eschenhagen T (2003) What is the role
of b-adrenergic signaling in heart failure? Circ Res 93:896–906
26. Mongillo M, McSorley T, Evellin S, Sood A, Lissandron V,
Terrin A, Huston E, Hannawacker A, Lohse MJ, Pozzan T,
Houslay MD, Zaccolo M (2004) Fluorescence resonance energy
transfer-based analysis of cAMP dynamics in live neonatal rat
cardiac myocytes reveals distinct functions of compartmentalized
phosphodiesterases. Circ Res 95:67–75
27. Movsesian MA (2002) PDE3 cyclic nucleotide phosphodiester-
ases and the compartmentation of cyclic nucleotide-mediated
signalling in cardiac myocytes. Basic Res Cardiol 97:I83–I90
28. Nikolaev VO, Bunemann M, Schmitteckert E, Lohse MJ,
Engelhardt S (2006) Cyclic AMP imaging in adult cardiac
myocytes reveals far-reaching b1-adrenergic but locally conﬁned
b2-adrenergic receptor-mediated signaling. Circ Res 99:1084–
1091
29. Patrizio M, Vago V, Musumeci M, Fecchi K, Sposi NM, Mattei
E, Catalano L, Stati T, Marano G (2008) cAMP-mediated
b-adrenergic signaling negatively regulates Gq-coupled receptor-
mediated fetal gene response in cardiomyocytes. J Mol Cell
Cardiol 45:761–769
30. Roberts NA, Haworth RS, Avkiran M (2005) Effects of bisin-
dolylmaleimide PKC inhibitors on p90
RSK activity in vitro and in
adult ventricular myocytes. Br J Pharmacol 145:477–489
31. Rochais F, Abi-Gerges A, Horner K, Lefebvre F, Cooper DMF,
Conti M, Fischmeister R, Vandecasteele G (2006) A speciﬁc
pattern of phosphodiesterases controls the cAMP signals gener-
ated by different Gs-coupled receptors in adult rat ventricular
myocytes. Circ Res 98:1081–1088
32. Schafer M, Ponicke K, Heinroth-Hoffmann I, Brodde OE, Piper
HM, Schluter KD (2001) Beta-adrenoceptor stimulation attenu-
ates the hypertrophic effect of alpha-adrenoceptor stimulation in
adult rat ventricular cardiomyocytes. J Am Coll Cardiol
37:300–307
33. Snabaitis AK, Muntendorf A, Wieland T, Avkiran M (2005)
Regulation of the extracellular signal-regulated kinase pathway in
adult myocardium: differential roles of Gq/11.G i and G12/13 pro-
teins in signalling by a1-adrenergic, endothelin-1 and thrombin-
sensitive protease-activated receptors. Cell Signal 17:655–664
34. Valverde AM, Sinnett-Smith J, van Lint J, Rozengurt E (1994)
Molecular cloning and characterisation of protein kinase D: a
target for diacylglycerol and phorbol esters with a distinctive
catalytic domain. Proc Natl Acad Sci USA 91:8572–8576
35. van Lint J, Sinnett-Smith J, Rozengurt E (1995) Expression and
characterisation of PKD, a phorbol ester and diacylglycerol-sti-
mulated serine protein kinase. J Biol Chem 270:1455–1461
36. Vandecasteele G, Rochais F, Abi-Gerges A, Fischmeister R
(2006) Functional localization of cAMP signalling in cardiac
myocytes. Biochem Soc Trans 34:484–488
37. Vega RB, Harrison BC, Meadows E, Roberts CR, Papst PJ, Olson
EN, McKinsey TA (2004) Protein kinases C and D mediate
agonist-dependent cardiac hypertrophy through nuclear export of
histone deacetylase 5. Mol Cell Biol 24:8374–8385
38. Verde I, Vandecasteele G, Lezoualc’h F, Fischmeister R (1999)
Characterization of the cyclic nucleotide phosphodiesterase sub-
types involved in the regulation of the L-type Ca
2? current in rat
ventricular myocytes. Br J Pharmacol 127:65–74
39. Yuan J, Bae D, Cantrell D, Nel AE, Rozengurt E (2002) Protein
kinase D is a downstream target of protein kinase Ch. Biochem
Biophys Res Commun 291:444–452
40. Zaccolo M (2006) Phosphodiesterases and compartmentalized
cAMP signalling in the heart. Eur J Cell Biol 85:693–697
41. Zaccolo M, Pozzan T (2002) Discrete microdomains with high
concentration of cAMP in stimulated rat neonatal cardiac myo-
cytes. Science 295:1711–1715
42. Zugaza JL, Sinnett-Smith J, Van Lint J, Rozengurt E (1996)
Protein kinase D (PKD) activation in intact cells through a pro-
tein kinase C-dependent signal transduction pathway. EMBO J
15:6220–6230
Basic Res Cardiol (2011) 106:51–63 63
123